Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome

Background: Short QT syndrome (SQTS) is a newly described ion channelopathy, characterized by a short QT interval resulting from an accelerated cardiac repolarization, associated with syncope, atrial fibrillation, and sudden cardiac death due to ventricular fibrillation. As therapeutic options in SQTS are still controversial, we examined antiarrhythmic mechanisms in an experimental model of SQTS.

[1]  Michel Haissaguerre,et al.  Short QT syndrome: clinical findings and diagnostic-therapeutic implications. , 2006, European heart journal.

[2]  J. Jalife,et al.  The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation , 2006, Journal of internal medicine.

[3]  R. Brugada,et al.  Short QT syndrome , 2005, Canadian Medical Association Journal.

[4]  I. Gussak,et al.  Short QT Syndrome , 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[5]  Peng-Sheng Chen,et al.  Action Potential Duration and QT Interval During Pinacidil Infusion in Isolated Rabbit Hearts , 2005, Journal of cardiovascular electrophysiology.

[6]  S. Priori,et al.  A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.

[7]  Ramon Brugada,et al.  Short QT Syndrome and Atrial Fibrillation Caused by Mutation in KCNH2 , 2005, Journal of cardiovascular electrophysiology.

[8]  G. Breithardt,et al.  Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. , 2005, Cardiovascular research.

[9]  Jingdong Li,et al.  Transgenic upregulation of IK1 in the mouse heart leads to multiple abnormalities of cardiac excitability. , 2004, American journal of physiology. Heart and circulatory physiology.

[10]  G. Breithardt,et al.  Comparison of the In Vitro Electrophysiologic and Proarrhythmic Effects of Amiodarone and Sotalol in a Rabbit Model of Acute Atrioventricular Block , 2004, Journal of cardiovascular pharmacology.

[11]  A. V. van Ginneken,et al.  Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.

[12]  Michel Haissaguerre,et al.  Short QT syndrome: pharmacological treatment. , 2004, Journal of the American College of Cardiology.

[13]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[14]  G. Tseng,et al.  Actions of pinacidil on membrane currents in canine ventricular myocytes and their modulation by intracellular ATP and cAMP , 2004, Pflügers Archiv.

[15]  Martin Borggrefe,et al.  Congenital Short QT Syndrome and Implantable Cardioverter Defibrillator Treatment: , 2003, Journal of cardiovascular electrophysiology.

[16]  Martin Borggrefe,et al.  Short QT Syndrome: A Familial Cause of Sudden Death , 2003, Circulation.

[17]  Ying Wang,et al.  KCNQ1 gain-of-function mutation in familial atrial fibrillation. , 2003, Science.

[18]  Wei Huang,et al.  KCNQ1 Gain-of-Function Mutation in Familial Atrial Fibrillation , 2003, Science.

[19]  G. Breithardt,et al.  Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[20]  M. Curtis,et al.  Limited Antifibrillatory Effectiveness of Clinically Relevant Concentrations of Class I Antiarrhythmics in Isolated Perfused Rat Hearts , 2002, Journal of cardiovascular pharmacology.

[21]  G. Breithardt,et al.  Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. , 2002, The Journal of pharmacology and experimental therapeutics.

[22]  J. Brugada,et al.  Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.

[23]  S. Viskin,et al.  Effects of Electrophysiologic‐Guided Therapy with Class IA Antiarrhythmic Drugs on the Long‐Term Outcome of Patients with Idiopathic Ventricular Fibrillation with or without the Brugada Syndrome , 1999, Journal of cardiovascular electrophysiology.

[24]  P. Kirchhof,et al.  Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. , 1998, Circulation.

[25]  G. Breithardt,et al.  Divergent Effect of Acute Ventricular Dilatation on the Electrophysiologic Characteristics of d,I‐Sotalol and Flecainide in the Isolated Rebbit heart , 1998, Journal of cardiovascular electrophysiology.

[26]  S. Hohnloser,et al.  Electrophysiologic Features of Torsades de Pointes: , 1997, Journal of cardiovascular electrophysiology.

[27]  M R Franz,et al.  The vulnerable period for low and high energy T-wave shocks: role of dispersion of repolarisation and effect of d-sotalol. , 1996, Cardiovascular research.

[28]  M R Franz,et al.  Computer Analysis of Monophasic Action Potentials: Manual Validation and Clinically Pertinent Applications , 1995, Pacing and clinical electrophysiology : PACE.

[29]  J. M. Di Diego,et al.  Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry? , 1993, Circulation.

[30]  M. Reiter,et al.  Electrophysiologic evaluation of cardiovascular agents in the isolated intact rabbit heart. , 1991, Journal of Pharmacological Methods.

[31]  S Nattel,et al.  Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. , 1990, Circulation.